

SUPPLEMENTARY MATERIAL

Table 1. Biologic's efficacy (omalizumab, mepolizumab, reslizumab, benralizumab) in patients with severe asthma and psychiatric comorbidity.

| Parameters | Before biologics | During biologics | Change | P value |
|---|---------------------------|-------------------------|--------------|----------|
| Efficacy parameters | | | | |
| FEV ₁ (L): mean, median (Q1-Q3) | 1.78, 1.60 (1.28 - 2.39) | 2.0, 1.91 (1.36 - 2.55) | +0.22, +0.31 | <0,001 * |
| FEV ₁ (%): mean, median (Q1-Q3) | 70, 67 (60 - 82) | 81, 82 (69.25 - 96) | +11, +15 | <0,001 * |
| FEF ₂₅₋₇₅ (%): mean, median (Q1-Q3) | 54, 44 (31.5 - 71.5) | 68, 58 (36 - 96) | +14, +14 | 0,187 |
| FEV ₁ /FVC (%): mean, median (Q1-Q3) | 63, 61 (55 - 72.5) | 66, 68 (58 - 74) | +3.0, +7.0 | 0,077 |
| FE _{NO} (ppb): mean, median (Q1-Q3) | 64, 41 (25 - 79) | 30, 25 (21 - 40) | -34.0, -16.0 | 0,101 |
| ACT score: mean, median (Q1-Q3) | 12.1, 12 (8.5 - 14) | 21, 22 (20 - 24) | +8.9, +10.0 | <0,001 * |
| Exacerbations: mean, median (Q1-Q3) | 3.33, 3.0 (2.0 - 4.0) | 0.9, 0.0 (0.0 - 1.0) | -2.43, -3.0 | <0,001 * |
| Exacerbations that required hospitalization: mean, median (Q1-Q3) | 0.6, 0.0 (0.0 - 1.0) | 0.18, 0.0 (0.0 - 0.0) | -0.42, -0.0 | 0,027* |
| Annual cumulative dose of OCS (mg): mean, median (Q1-Q3) | 1714, 1000 (612.5 - 1800) | 610, 0.0 (0.0 - 759) | -1104, -1000 | 0,001* |
| T2 Biomarkers | | | | |
| Peripheral eosinophilia (cells/uL): mean, median (Q1-Q3) | 580, 300 (200 - 600) | 142, 100 (0 - 200) | -438, -200 | 0,008* |
| Total IgE (kU/L): mean, median (Q1-Q3) | 382, 154 (51.5 - 458) | 335, 140 (46.45 - 315) | -47, -14 | 0,238 |

Abbreviations: FEV₁, forced expiratory volume in 1 s; FEF₂₅₋₇₅, forced expiratory flow at 25-75%; FVC, forced vital capacity; FE_{NO}, fractional exhaled nitric oxide; ACT, asthma control test; OCS, oral corticosteroids.

*Statistically significance difference.